TFC Financial Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$157K Buy
316
+9
+3% +$3.99K 0.02% 164
2026
Q1
$137K Hold
307
0.02% 167
2025
Q4
$139K Sell
307
-1
-0.3% -$431 0.02% 163
2025
Q3
$121K Sell
308
-15
-5% -$6.27K 0.02% 175
2025
Q2
$144K Hold
323
0.02% 156
2025
Q1
$157K Hold
323
0.02% 142
2024
Q4
$130K Hold
323
0.02% 161
2024
Q3
$150K Buy
323
+10
+3% +$4.8K 0.02% 149
2024
Q2
$147K Buy
313
+162
+107% +$70.3K 0.03% 144
2024
Q1
$63.1K Buy
151
+1
+0.7% +$423 0.01% 214
2023
Q4
$61K Hold
150
0.01% 211
2023
Q3
$52.2K Hold
150
0.01% 215
2023
Q2
$52.8K Buy
150
+3
+2% +$1.01K 0.01% 216
2023
Q1
$46.3K Buy
147
+4
+3% +$1.2K 0.01% 236
2022
Q4
$41.3K Buy
143
+16
+13% +$4.88K 0.01% 211
2022
Q3
$37K Buy
127
+18
+17% +$5.18K 0.01% 215
2022
Q2
$31K Buy
109
+40
+58% +$10.7K 0.01% 228
2022
Q1
$18K Buy
69
+22
+47% +$5.22K 0.01% 270
2021
Q4
$10K Hold
47
﹤0.01% 340
2021
Q3
$9K Hold
47
﹤0.01% 345
2021
Q2
$9K Hold
47
﹤0.01% 330
2021
Q1
$10K Sell
47
-18
-28% -$3.95K ﹤0.01% 312
2020
Q4
$15K Sell
65
-4
-6% -$918 0.01% 286
2020
Q3
$19K Buy
+69
New +$19K 0.01% 238

Other funds holding VRTX

TFC Financial Management's VRTX Position: Q2 2026 in Review

TFC Financial Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.9% in Q2 2026, buying an estimated $3.99K and bringing the position to 316 shares worth $157K. The position accounts for 0.02% of the portfolio, ranked #164.

TFC Financial Management first reported a position in VRTX in Q3 2020 and has held it in 24 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • TFC Financial Management held 316 shares of Vertex Pharmaceuticals worth $157K as of Q2 2026.
  • TFC Financial Management bought 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
  • Vertex Pharmaceuticals made up 0.02% of TFC Financial Management's portfolio in Q2 2026, its #164 holding.
  • TFC Financial Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on TFC Financial Management's 13F filing for Q2 2026, filed 23 Jul 2026.